
With recent approval of the minor groove binding agent zzso in Europe for the treatment of patients with soft tissue zzso there has been renewed interest in minor groove zzso Though previously considered to be without clinical value due to their initial significant zzso new minor groove zzso are emerging which are challenging that zzso zzso in the most recently completed and ongoing trials have been easily zzso These agents have zzso zzso activity against a wide variety of tumor types including zzso zzso zzso breast and zzso zzso zzso these agents according to a particular zzso context of vulnerability might reveal previously zzso applications for this diverse class of zzso This review provides a look at how minor groove binding agents have progressed from the lab through the clinic with particular emphasis on identifying the contexts of vulnerabilities of patient tumors which increase the effectiveness of these zzso 

